Krishna Nagalla

Krishna Nagalla has a strong background in scientific research and pharmaceutical development. Krishna is currently working as a Sr. Scientist 1 at Maze Therapeutics since October 2022. Prior to that, they worked at Amgen for 6 years, starting as an Associate scientist in December 2016 and eventually becoming a Sr. Associate Scientist until November 2022.

Before joining Amgen, Krishna worked as a Postdoctoral Fellow at Arena Pharmaceuticals from June 2014 to January 2016. Krishna'srole involved conducting early stage discovery and development of cardio-protective compounds, with a focus on heart failure and remodeling. Krishna also designed and validated in vivo animal models to assess cardiac structural and functional changes post myocardial infarction and reperfusion injury, using techniques such as Millar catheterization and Pressure-Volume Admittance catheterization.

Prior to their industry experience, Krishna worked at the University of Mississippi as a Research Assistant from August 2010 to May 2014. Krishna performed protein analysis studies and conducted in vivo studies to investigate the role of Specific COX-2 inhibition in attenuating cardiac remodeling. Krishna also completed their Doctoral Thesis at the university, where they designed and executed in vivo small animal studies to identify and validate the efficacy of specific prostaglandin receptors as drug targets for cardiac remodeling. Additionally, they worked as a Teaching Assistant at the university from August 2009 to July 2012.

Overall, Krishna Nagalla has a diverse and extensive background in scientific research and pharmaceutical development, with a focus on cardiovascular health and drug discovery.

Krishna Nagalla completed a Bachelor of Pharmacy (B.Pharm.) degree in Pharmacy at Osmania University from 2005 to 2009. Subsequently, from 2009 to 2014, they pursued a Doctor of Philosophy (PhD) in Pharmacology at the University of Mississippi.